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Abstract
Background: Studies have provided important findings about the roles of Notch signaling in neural
development. Unfortunately, however, most of these studies have investigated the neural stem cells
(NSCs) of mice or other laboratory animals rather than humans, mainly owing to the difficulties
associated with obtaining human brain samples. It prompted us to focus on neuroectodermal
spheres (NESs) which are derived from human embryonic stem cell (hESC) and densely inhabited
by NSCs. We here investigated the role of Notch signaling with the hESC-derived NESs.
Results: From hESCs, we derived NESs, the in-vitro version of brain-derived neurospheres. NES
formation was confirmed by increased levels of various NSC marker genes and the emergence of
rosette structures in which neuroprogenitors are known to reside. We found that Notch signaling,
which maintains stem cell characteristics of in-vivo-derived neuroprogenitors, is active in these
hESC-derived NESs, similar to their in-vivo  counterpart. Expression levels of Notch signaling
molecules such as NICD, DLLs, JAG1, HES1 and HES5 were increased in the NESs. Inhibition of
the Notch signaling by a -secretase inhibitor reduced rosette structures, expression levels of NSC
marker genes and proliferation potential in the NESs, and, if combined with withdrawal of growth
factors, triggered differentiation toward neurons.
Conclusion: Our results indicate that the hESC-derived NESs, which share biochemical features
with brain-derived neurospheres, maintain stem cell characteristics mainly through Notch signaling,
which suggests that the hESC-derived NESs could be an in-vitro model for in-vivo neurogenesis.
Background
Neural stem cells (NSCs), which have properties of self-
renewal and differentiation into neurons and glias, are
usually isolated from fetal and adult brains in the form of
floating clonal derivatives of the NSCs placed in culture,
known as neurospheres (NSs) [1-3]. NSCs have the poten-
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tial to be used in cell replacement therapy for neural dis-
orders such as Parkinson's disease and Alzheimer's disease
as well as other neurological disorders including spinal
cord injuries [4]. For therapy, maintenance and expansion
of the NSCs are necessary to provide sufficient amount of
cells for patients to be treated.
Human NSCs can be obtained from brains and from
human embryonic stem cells (hESCs) by a step-wise dif-
ferentiation procedure [5-8], and such hESC-derived
NSCs are usually cultured as NS-like aggregates. However,
the NS-like aggregates, also called neuroectodermal
spheres (NESs; [9]), differ from the NSs in that NESs have
a distinctive radial cluster of columnar epithelial cells,
called a rosette [8,10]. The rosette resembles a developing
neural tube and contains multipotential neuroprogenitor
cells that have a similar expression profile as the neuroep-
ithelial cells in the neural tube. Analyses of microarray
data revealed that brain-derived NSCs and hESC-derived
NSCs were shown to express distinct groups of genes and,
nonetheless, they did share many properties involving
NSC markers [11,12]. In addition, the brain-derived NSs
generally exhibit specific regional markers along with
dorso-ventral and antero-posterior axes and, of them,
hESC-derived NESs tend to preferentially express markers
of anterior neural ectoderm [12]. Together, NESs might be
assumed to mimic the pattern of in vivo neurogenesis to a
degree [13].
It is well known that Notch signaling has a role in decid-
ing cell fates during development [14]. With regard to
neural development, Notch signaling also has an impor-
tant role in the maintenance of neural stem-cell features.
Notch1, Presenilins and RBP are key Notch signaling mol-
ecules  a receptor, a regulator and a co-effector, respec-
tively. In the fetal brains of Notch1-/-, Presenilins-/-, or
RBP-J-/- mice, NSC levels were shown to be completely
depleted [15]. Also, inactivation of Notch-regulated genes
such as Hes1 and Hes5 induced a premature neuronal dif-
ferentiation during brain development [16]. Studies with
Presenilin-deficient mice have shown that Notch signal-
ing is necessary to maintain all NSCs, regardless of their
locations in the brain or age of the mouse [17]. Several
studies have provided important findings about the roles
of Notch signaling in neural development; unfortunately,
however, most of these studies have investigated the NSCs
of mice or other laboratory animals rather than humans,
mainly owing to the difficulties associated with obtaining
human brain samples. Therefore, information on human
NSCs is scarce, which prompted us to focus on neuroecto-
dermal spheres (NESs) which are derived from human
embryonic stem cell (hESC) and densely inhabited by
NSCs. hESC-derived NSCs could possibly replace the rare
human NSCs [4], which highlights the importance of the
study to characterize the complicated, web-like molecular
events, including Notch signaling, that occur in the in
vitro-produced NESs.
In this study, we investigated the role of Notch signaling
in hESC-derived NESs. We first verified that hESC-derived
NESs had features similar to neurospheres derived in vivo.
We demonstrated that Notch-related molecules were
expressed at higher levels in the NESs than in the hESC-
derived embryoid bodies. Furthermore, when Notch sign-
aling was inhibited by a specific inhibitor for the -secre-
tase, the rosette folds were not visible, and the self-
renewing activity and the proliferative potential were sig-
nificantly reduced in the resulting NESs. These observa-
tions indicate that Notch signaling is active in the NESs,
and, to our knowledge, this, along with a recent paper by
Elkabetz et al. [12], is the first description about the role
of Notch signaling in maintaining self-renewal of NSCs
derived from hESCs.
Methods
Human embryonic stem cell (hESC) culture
CHA-hES3 [18] was maintained on mitomicin C-treated
STO feeder cells (ATCC, Manassas, Virginia, USA). H9
[19] (WiCell, USA) was maintained on -irradiated mouse
embryonic fibroblasts in gelatin-coated culture dishes at
37°C, 5% CO2 in air. These hESCs were sub-cultured by
mechanical section using a hand-made glass pipette.
Human ESCs were cultured in DMEM/F12 containing
20% serum replacement, 0.1% non-essential amino acids,
0.1 mM -mercaptoethanol, 100 U/ml penicillin-strepto-
mycin and 4 ng/ml basic fibroblast growth factor
(bFGF)(All from Invitrogen, Carlsbad, USA). Culture
media were replenished everyday. Our research was per-
formed under ethical approval from the Institutional
Review Board (IRB) at KRIBB.
Generation and culture of Neuroectodermal spheres 
(NESs) from hESCs
Human ESC colonies were dissected into 500 m squares
by tissue chipper [20] or ESCD with 500 m pattern [21],
transferred to plastic Petri dishes containing EB medium
(hESC medium plus 10% serum replacement without
bFGF), and cultured for 7 days. EB medium was then
replaced to neuroectodermal sphere medium (NSM;
DMEM:F12(1:1 in volume), B27 supplement (1:50), N2
supplement (1:100), 100 U/ml penicillin-streptomycin,
20 ng/ml bFGF, 20 ng/ml human epidermal growth factor
(EGF) (all from Invitrogen) and 10 ng/ml human leuke-
mia inhibitory factor (LIF, Sigma, St. Louis, MO)). A half
medium was refreshed in every 48 hours. NESs were sub-
cultured using McIlwain tissue chopper (Mickle Engineer-
ing, Gomshall, Surrey, UK) when they were grown to 500
m in diameter [22]. Volume of NESs was measured by
the formula for the volume of sphere, (4/3)r3; radiuses ofBMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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individual spheres were determined by taking mean
length of long and short axis.
RT-PCR analysis
Total RNA was isolated from hESCs, EB and NESs using
RNesay kit (Qiagen, Valencia, UAS) and reverse-tran-
scribed into cDNA with Superscript First Strand Synthesis
System (Invitrogen) using oligo-d(T) primer as described
in the manufacture's instructions. As a reference, the tran-
scripts of GAPDH (for glyceraldehydes-3-phosphate dehy-
drogenase) or -actin  gene were amplified. Sequence
information of primers and the lengths of amplified prod-
ucts are seen in Additional file 1. Primers for amplifying
CNS marker genes are listed elsewhere [23]. Amplification
conditions were as follows: single cycle of 94°C for 5 min
followed by 30  35 cycles of 94°C for 30 s, 5660°C for 30
s and 72°C for 30 s, and the final single cycle of 72°C
extension for 7 min. Products were analyzed on 1.5% aga-
rose gel and visualized by ethidium bromide staining.
Immunocytochemistry
Floating NESs were plated on the matrigel (BD Bio-
sciences, San Jose, CA)-coated dishes. The NESs attached
were fixed with 10% formalin solution (containing 4%
formaldehyde, Sigma) for 20 min followed by permeabi-
lization for 30 min in PBS containing 0.1% Triton X-100.
After blocking with 4% normal donkey serum (Molecular
Probes, Eugene, OR, USA) for 1 hour, the samples were
incubated with following primary antibodies at 4°C over-
night: antibodies for Nestin (1:200, Chemicon, Temecula,
CA), PAX6 (1:50, DSHB, Iowa City, Iowa, USA), NOTCH1
(bTAN20, 1:50, DSHB), DLL1 (1:200, Santa Cruz Biotech-
nology, CA, USA), TUJ1 (1:500, Covance, Madison, Wis-
consin, UAS), JAG1 (1:50, Santa Cruz Biotechnology), N-
Cadherin (1:50, Santa Cruz Biotechnology). Primary anti-
bodies were detected by using Cy2- or Cy3-conjugated
Donkey anti-Goat, anti-rabbit or anti-mouse secondary
antibodies (Jackson laboratories, West Grove, PA, USA)
for 45 min at room temperature. After reaction with sec-
ondary antibodies, the cells were stained with 100 nM
DAPI (4',6-diamidino-2-phenylindole)(Molecular
Probes) for 5 min, and mounted. Fluorescence-labeled
NESs were viewed under an IX51 Olympus fluorescence
microscope (Olympus, Japan) or Axiovert 200M
equipped with ApoTom (Carl Zeiss, Gottingen, Ger-
many).
Neuroectodermal sphere re-forming Assay
NESs were dissociated with 2 mg/ml collagenase into sin-
gle cells and cultured in NSM containing 0.1% DMSO or
5 M DAPT for 17~18 days at a density of 1 × 105 cells/ml.
Fifty percent of medium was replaced every 4~5 days.
NESs with sizes more than 50 m were counted.
BrdU incorporation assay
Cells cultured in the NSM were treated with 10 M 5-
bromo-2'deoxyurine (BrdU; Roche Molecular Biochemi-
cals, Sussex, UK) for 24 hours. Spheres were dissociated
with collagenase and plated on the matrigel-coated cover-
slip for counting. Cells were fixed with formalin solution
10% (Sigma) for 15 min followed by permeabilization for
30 min in PBS containing 0.1% Triton X-100. DNA dena-
turation were performed by 2N HCl for 10 min and neu-
tralized with 0.1 M Sodium tetra-borate for 10 min.
Following procedures were the same as immunocyto-
chemical method above mentioned. Genome-integrated
BrdUs were detected using anti-BrdU antibody (1:200, BD
pharmingen, San Diego, USA) and Cy3 conjugated anti-
mouse secondary antibody. The proportion of BrdU posi-
tive cells relative to total cells counted was estimated
under a fluorescent microscope.
Trypan blue staining
NESs cultured in the NSM containing 0.1% DMSO or 5
M DAPT for 4 days were dissociated with 2 mg/ml colla-
genase into single cells. An equal volume of Trypan blue
stain solution (0.4%, Invitrogen) was added to the cell
suspension. After 5 min, trypan blue stained cells and
total cells were counted using a hemacytometer under the
IX51 Olympus inverted microscope (Olympus).
Quantification of TUJ1-positive cells in NESs
After 4 day culture in the NSM containing 0.1% DMSO or
5 M DAPT, NESs were dissociated into single cells with 2
mg/ml collagenase and allowed to attach on the matrigel-
coated coverslip. After immunostaining either with Nestin
or TUJ1 antibody, the proportion of Nestin- or TUJ1-pos-
itive cells relative to the whole cells counted was calcu-
lated.
Western blot analysis
Antibodies against Jagged1 (JAG1, Santa Cruz Biotechnol-
ogy), Delta-like-1 (Dll1; Santa Cruz Biotechnology),
cleaved Notch1 (NICD; Cell Signaling Technology, Bever-
ley, MA USA), Nestin (Chemicon), TUJ1 (Covance, Rich-
mond, CA), MAP2 (Chemicon), S100 (Abcam,
Cambridge, UK), GFAP (Novus Biologicals, Littleton, CO,
USA), NG2 (Chemicon), CNPase (Chemicon), HES1
(Chemicon) and HES5 (Sigma) were used for Western-
blot analyses. For protein extraction, cells were lysed in a
buffer containing 20 mM HEPES, 50 mM NaCl, 10% glyc-
erol, 0.5% Triton X-100 and 2% -mercaptoethanol. Con-
centrations were determined by the Bradford method. The
protein samples (20 g) were separated by 6%, 8% and
15% SDS-PAGE and transferred to a nitrocellulose mem-
brane (Schleicher and Schuell Inc., Keene, NH, USA) with
Tris-glycine-methanol buffer (25 mM Tris, 192 mM gly-
cine and 20% methanol). After blocking with the TBS
buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl) contain-BMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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ing 5% non-fat dry milk and 0.1% Tween20, the mem-
brane was incubated with primary antibodies, followed
by incubation with horseradish peroxidase-conjugated
goat antibody to rabbit IgG (Santa Cruz Biotechnology),
and developed with enhanced chemiluminescence rea-
gent (Amersham, Piscataway, NJ, USA).
Results and Discussion
Derivation and characterization of neuroectodermal 
spheres from human embryonic stem cells
We derived NESs containing neuroprogenitors from the
hESCs CHA3-hESCs [18] and H9 [19]. Figure 1A shows
the procedure and timetable of NES preparation. We used
a tissue chopper [20] or embryonic stem cell divider
(ESCD) [21] to prepare embryoid bodies (EBs); both of
these approaches produce regular-sized, square clumps of
hESCs (500 m in length, Figure 1Bb). These clumps were
cultured in EB medium (EBM) for 7 days (Figure 1Bc) and
transferred to NES medium (NSM) to further differentiate
into NESs. Neural rosettes, which are structures with neu-
ral tube-like folds and central cavities surrounded by rings
of small columnar cells [8], appeared about 2 days after
the first subculture (Figure 1A, D16(NES)). This was char-
acteristic of NESs (Fig 1Bd).
The hESC-derived NESs attached to the Matrigel-coated
culture dish were immunostained for neural stem cell
(NSC) markers such as SOX1, PAX6 and Nestin. The
rosettes of various sizes were positively stained for all
these NSC markers (Figure 1C). In addition, the hESC-
derived NESs were stained for a neuronal marker TUJ1, we
found TUJ1-positive neurites sporadically scattered
around the boundaries of NES clumps. Flow cytometry
showed that more than 95% in both CHA-hES3- and H9-
derived NESs were positively stained for the neural precur-
sor cell surface marker PSA-NCAM [24](data not shown).
When analyzed at the transcriptional level, the NESs
showed increased expression levels of NSC marker genes
such as NES, MSI1 and 2, PAX6, VIM, SOX1, and SOX3,
whereas none of the mesoderm-lineage markers (Meso;
VEGFR2, C-KIT, GATA2 and T) or the endoderm-lineage
markers (Endo; AFP and GATA4) were transcribed in a
NES-specific manner (Figure 1D). The transcripts for the
ESC marker genes (Stem) OCT4 and NANOG, were unde-
tectable in the NESs. The expression patterns of these NSC
markers are similar to recent reports; for example, PAX6
expression continued in 7-day-old EBs, whereas SOX1
expression began only after NES formation [10]. RT-PCR
results showed that anterior CNS markers such as FoxG1
and Otx2 were more expressed in the NESs than mid-
hindbrain markers such as Pax2 and En1 and markers of
posterior CNS fate such as Krox20 and HoxB4 [23] (Figure
1E). This result agreed with a recent report [12], suggesting
that in the absence of extrinsic patterning cue, NESs
acquire markers defining anterior CNS identity. Taken
together, these morphological, immunocytochemical,
and molecular-level results demonstrate that the hESC-
derived NESs are suitable as an in vitro model of human in
vivo-derived neuroprogenitors.
Components of Notch signaling were up-regulated in 
hESCs-derived NESs
Notch signaling has been proposed to maintain the prop-
erty of neuroprogenitors obtained from brain samples
[17,25,26]. To investigate the role of Notch signaling in
the NESs, we first profiled expressions of Notch signaling
genes. RT-PCR was used to show that transcripts for recep-
tors NOTCH1, NOTCH2 and NOTCH3 were present at
slightly increased levels in the NESs compared with hESCs
and EB (Figure 2A). The NOTCH ligands DLL1, DLL3 [15]
and JAG1 [27] were abundantly expressed in the NESs.
However, the NOTCH4 transcript was not detected either
from hESCs or NESs (data not shown); this is in agree-
ment with a previous report [28]. Both HES1 and HES5,
which are regulated by Notch signaling and involved in
neurogenesis [29], were markedly expressed in the NESs;
they were also expressed in undifferentiated hESCs in a
small amount as observed before (13, 25, 26, 42, 43).
HEY1 and HEY2, which are also regulated by Notch sign-
aling but are associated with vascular development [30],
were not preferentially expressed in the NESs. MIB1 and
MIB2 [31], which are required for ligand activation, and
PSEN1, which is the catalytic subunit of -secretase that
cleaves NOTCH receptor to release the major signal trans-
mitter, NOTCH intracellular domain (NICD) [32], were
also shown to be expressed at high levels in the NESs.
Expression of Notch signaling molecules were also con-
firmed at the protein level. In agreement with the RT-PCR
results, Notch signaling pathway proteins such as JAG1
and DLL1 and NICD and the target gene products HES1
and HES5 were abundant in hESC-derived NESs (Figure
2B). When the attached NESs were stained for JAG1 or
DLL1, each of which is a transmembrane NOTCH ligand,
JAG1 and DLL1 signals (Figure 2Ca and 2Cb, respectively)
were shown to be enriched in the rosettes and were at par-
ticularly high levels in the inner circle of the rosette struc-
tures, facing the luminal side (Figure 2C). We also found
that NOTCH1 receptor was also localized at the luminal
side of rosettes together with JAG1 (Figure 2Cc) and DLL1
(Figure 2Cd). It has been shown that JAG1 specifically
expressed neuroepithelial cells in apical termini of fetal
brain [33]. The JAG1 staining pattern was in agreement
with N-cadherin signal and formed a belt- or adherens
junction-like signal. In a similar vein, it was reported that
in the ventricular zone, DLL1 is linked with adherens
junction through interaction with MAGI1 at the apical ter-
mini of processes to activate Notch on neighboring cells
in the developing central nervous system [34]. Owing to
the stacking property of the cells facing the luminal side of
rosettes, it is difficult to find out whether both notch lig-BMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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and and receptor are expressed within the same cells. Nev-
ertheless, it is worth to notice a recent study that both
Notch1 and Dll1 co-existed in ependymal cells [35].
Together, these findings indicate that Notch signaling has
a greater role in cellular function in the hESC-derived
NESs than in the hESCs and EBs [36]. On the whole, the
gene expression profile of the hESC-derived NESs corre-
sponded with the previously reported results using in vivo
NSCs [15,16,26,37,38], which indicates that the neuro-
progenitors in the NESs/rosettes express many of the same
genes that are expressed in neuroepithelial cells of the
neural tube.
Inhibition of Notch signaling leads to a loss of the stem cell 
characteristics from the neuroectodermal spheres
After demonstrating that Notch signaling is active in the
NESs, we investigated the potential role of Notch signal-
ing in the NESs derived from hESCs. We treated the NESs
with the Notch signaling inhibitor, N-[N-(3,5-difluoroph-
enacetyl)-L-alanyl]-S-phenylglycine-t-butyl ester (DAPT),
which is known to specifically bind to Presenilin-1 (PS1)
and inhibit -secretase activity [28]. Surprisingly, in both
CHA3 and H9 cell lines, the treatment with 5 M DAPT
removed the rosette structures from most of the floating
(Figure 3A, CHA3 data only shown) and attached NESs
(Figure 3B, H9 data only shown). The volume of floating
NESs after DAPT treatment was 0.039 ± 0.027 mm3;
(mean ± standard deviation (SD); n = 58), and this value
was only 59% of the value of DMSO control (0.066 ±
0.042 mm3; n = 44; p < 0.001) (Figure 3C). DAPT treat-
ment did not cause damages such as cell death, as evi-
denced by the observation that trypan-blue staining
showed that the survival rates were almost equal between
DMSO only (97.7 ± 0.4, mean ± SD; n = 659) and DAPT
(98.9 ± 1.3; n = 706) groups. Considering that the rosette
contains neuroprogenitor cells reside [8], the reduced
numbers of rosette structure in the NESs after treatment
with a Notch inhibitor could indicate a reduction in the
neuroprogenitor population. In agreement with this, RT-
PCR results from the DAPT-treated NESs derived from
both hESC cell lines showed a marked reduction in the
expression levels of various NSC marker genes and Notch-
regulated target genes such as HES1 and HES5 (Figure
3D).  NGN1, which is suppressed by HES5  expression,
were de-repressed in the DAPT-treated NESs in both
CHA3 and H9 hESCs. MASH1 is another target gene that
is negatively regulated by HES5, but its de-repression after
DAPT treatment was not as immediate as that of NGN1.
To assess the proliferating capacity of neuroprogenitors in
the Notch signaling-inhibited NESs, we performed NES-
reforming assay [15,26,39]. NESs were enzymatically dis-
sociated into single cells and allowed to re-construct
sphere colonies in NSM with or without DAPT. As shown
in Figure 3E, the number of emerging spheres in the
DAPT-treated cells was reduced to 25% that of the control
group in CHA3 (of 105 cells plated, 29.7 ± 4.7 (mean ±
standard error) and 7.9 ± 2.2 cells in DMSO control and
DAPT-treated cells, respectively; p < 0.05) and H9 (55.1 ±
1.8 cells for control vs 13.0 ± 1.2 cells for DAPT-treated
group; p < 0.005) cell line s. The reformation frequency of
hESC-derived sphere colony has not previously been esti-
mated with hESC-derived NESs, making it impossible to
compare the reformation efficiency, but it seems to be
about ten-fold less than the frequency (2.4%) of mouse
neuroprogenitors derived in vivo [40]. In addition, results
of the bromo-2'-deoxyuridine (BrdU) incorporation assay
showed that DAPT treatment reduced the proportion of
replicating cells to 39% of the control group for CHA3
hESCs or 60% of the control group for H9 hESCs (Figure
Controlled derivation of neuroectodermal spheres from human embryonic stem cells Figure 1 (see previous page)
Controlled derivation of neuroectodermal spheres from human embryonic stem cells. (A) Schematic showing 
neuroectodermal sphere (NES). By a simple medium change without an attachment step, embryoid bodies (EBs) could be dif-
ferentiated to NESs harboring neuroprogenitor cells. EBs were grown in EBM for a week and then transferred to NSM supple-
mented with growth factors. The first subculture was performed one week later (D14) and, about two days later (D16), 
rosette-containing NESs appeared. The NES samples we used were D21 NESs, if not otherwise indicated. (B) Photographs of 
differentiating cell clumps at indicated times. Human embryonic stem cell (hESC) colonies (a) were divided into regular-sized 
(500 m in length) clumps (b) using a chopper. Floating EBs at day 7 (c) are shown. NESs at day 21 have prominent rosette-like 
folded structures in the spheres (d). We piled up EBs and NESs in single spots before taking pictures. (C) Expression of neural 
stem cell (NSC) markers in NESs. NESs were allowed to attach to culture equipment and were stained either for SOX1 (a), 
PAX6 (b), Nestin (NES, c) and TUJ1 (d). TUJ1-positive neurites are scattered, usually around the boundaries of NES clumps 
(arrows). Boundaries of rosettes are indicated by dotted circles. (D) RT-PCR for various marker genes of different cell line-
ages. NSC marker genes are abundantly transcribed in hESC-derived NESs (right panel). Other lineage markers such as those 
of ESCs (Stem), mesoderm lineage cells (Meso) and endoderm lineage cells (Endo) are not preferentially expressed in NESs 
(left panel). -Actin (ACTB), internal control. (E) RT-PCR analysis for markers of anterior regional identity (FB; FOXG1 and 
OTX2), mid-hind brain markers (MB/HB; PAX2 and EN1), and posterior CNS markers (HB; KROX20 and HOXB4). Scale 
bars, 200 m in B and 100 m in C; EBM, embryoid body medium; NSM, neurosphere medium; bFGF, basic fibroblast growth 
factor; EGF, epidermal growth factor; LIF, leukemia inhibitory factor.BMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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3F). Together, these results show that the Notch signaling
is mainly involved in the maintenance of rosette struc-
tures, the biochemical roles of which are probably linked
to maintenance and self-renewal of the neuroprogenitor
population in NESs.
Inhibition of Notch signaling drives neuroectodermal 
spheres to differentiate into neuronal cells
We also investigated the effects of Notch inhibition by
DAPT. RT-PCR analyses for the expressions of neuropro-
genitor marker genes and Notch-related genes showed
that DAPT treatment of NESs resulted in a marked change
in the gene expression profile (Figure 3D). In general,
Notch inhibition induces neuroprogenitor cells to differ-
entiate to neuronal cells in vertebrate and invertebrate
(for review, see [3]). We examined whether the hESC-
derived NESs displayed a similar trend of differentiation.
Immunostaining of the DAPT-treated NESs for 4 days
showed that neurite formation was markedly increased
compared with the DMSO control, as shown by -TUJ1
antibody staining (Figure 4A). We counted the number of
TUJ1-positive cells after dissociation of NESs into single
cells. The proportion of TUJ1-positive cells was 4.2 ± 1.8%
(mean ± standard deviation) and 31.5 ± 8.1% in DMSO
control and DAPT-treated NESs, respectively (p < 0.005;
Figure 4B). As a reference, the proportion of Nestin-posi-
tive cells was 76.2 ± 3.7%and 32.6 ± 9.2% in DMSO con-
trol and DAPT group, respectively (p < 0.001; Figure 4C).
Western-blot analyses showed that expression levels of
neuronal markers such as TUJ1 and MAP2 were increased
Notch signaling is active in neuroectodermal spheres derived from human embryonic stem cells Figure 2
Notch signaling is active in neuroectodermal spheres derived from human embryonic stem cells. (A) Transcrip-
tional expression of Notch signaling members in neuroectodermal spheres (NESs). All components functionally related with 
Notch signaling pathway were up-regulated in the NES samples. NOTCH4 was not expressed in all samples (data not shown). 
HEY1 and HEY2 were not preferentially expressed in the NESs, because they are regulated by Notch signaling but are associ-
ated with vascular development [30]. GAPDH, loading control. (B) Western-blot analyses of Notch signaling molecules in the 
NESs. All proteins of the Notch signaling pathway examined were expressed in hESCs, EBs and NESs but all were most abun-
dant in the NES protein extracts. NICD, NOTCH Intracellular Domain (or cleaved Notch1). -TUBULIN, loading control. (C) 
Immunostaining of the rosettes for the Notch ligands (JAG1 and DLL1) and receptor (NOTCH1). Rosettes structures derived 
from hESC-derived NESs were visualized using the rosette marker N-cadherin (N-CAD) and shown to locate to the inner rims 
of the rosettes. Both JAG1 (a and c) and DLL1 (b and d) transmembrane ligands are localized in the regions where N-cadherin 
signals exist. Anti-NOTCH1 antibody, which recognizes both NICD and C-terminal cytoplasmic domain of membrane-bound 
NOTCH1 receptor simultaneously, generates a rather diffused signal (c and d); nevertheless, its location at the luminal side of 
rosette is evident. Scale bars, 100 m.BMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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Figure 3 (see legend on next page)BMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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in DAPT-treated NESs, while not the levels of glial markers
such as GFAP, S100, NG2 and CNPase (inset in Figure
4B). These results indicate that DAPT-mediated Notch
inhibition enriches neuronal cell population in the NESs.
Moreover, withdrawal of growth factors (GFs) such as
fibroblast growth factor 2 (FGF2), leukemia inhibitory
factor (LIF) and epidermal growth factor (EGF) [41] from
the NSM furthered differentiation of the hESC-derived
NESs into neuronal cells (Figure 4D), agreeing with previ-
ous reports [42,43]. In the absence of GFs, DAPT treat-
ment resulted in accumulation of neurite bundles about
NESs (see arrows in Day8 and Day12), in contrast to the
samples treated with both GF and DAPT in which neurite
bundles were hardly detected. These results coincided
with the RT-PCR result in Figure 3D where Notch inhibi-
tion resulted in silencing HES1 and HES5 genes, which in
turn continued to de-repress pro-neuronal genes such as
NGN1 and MASH1 [29,38]. Meanwhile, the GF-negative
DMSO control at day 8 and 12 still possessed rosettes, the
sizes of which, however, were tiny compared with those of
GF-positive DMSO control. This leads to a speculation
that small-sized rosettes are supposed to be gradually
fused together to large-sized ones and, in this process, GFs
play roles in facilitating the presumable fusion event
among individual rosettes. Together, our results indicate
that inhibition of Notch signaling disturbs the self-
renewal of neuroprogenitors in the hESC-derived NESs
and leads ultimately to differentiation to neuronal cells.
However, we should keep in mind that the -secretase that
is inactivated by DAPT not only cleaves Notch receptors
but also other proteins (for review, see [44]). For confir-
mation that Notch inhibition indeed directs neuronal dif-
ferentiation, evidence needs to be provided supporting
that the DAPT effects on rosette structure can be rescued
with exogenous NICD expression in DAPT-treated cul-
tures, or be mimicked by knockdown experiments for
NICD or RBP.
NSCs have considerable therapeutic values in cell-replac-
ing regenerative treatment of currently incurable neural
diseases. In addition, unlimited supply of functional
human neurons is only possibly from NSCs, and this
would allow a fast and effective high throughput screen-
ing for neural disease therapies. Human ESCs are
undoubtedly the preferred source of NSCs. We have devel-
oped a simple method for deriving NSCs or neuroprogen-
itors from hESCs, with an emphasis on minimizing the
degree of variation among individual EBs and sphere col-
onies through size regulation (Figure 1A). The use of sub-
culture devices such as tissue chopper [20] or ESCD [21]
allowed us to obtain EBs with regular sizes (Figure 1B)
that form homogeneous NESs. Our method of NES deri-
vation has the advantages of a short culture period, thus
avoiding additional attachment and selection steps [10].
This markedly simplifies the current NES derivation pro-
cedures [6,8,45,46] without reducing the efficiency, which
is necessary for the practical application of hESC-derived
NSCs to cell therapeutics and drug screening. Our NES
derivation protocol is similar to a recently reported proto-
col [5].
In vertebrate, activation of Notch signals inhibits neuro-
nal differentiation and maintains the stem-cell character-
istics of NSCs or neuroprogenitors derived in vivo [3]. We
investigated whether Notch signaling is active and there-
Notch inhibition disturbs the maintenance of stem cell characteristics of neuroprogenitor cells in the hESC-derived neuroecto- dermal spheres Figure 3 (see previous page)
Notch inhibition disturbs the maintenance of stem cell characteristics of neuroprogenitor cells in the hESC-
derived neuroectodermal spheres. (A) Disappearance of the rosette structure with DAPT treatment. Neuroectodermal 
spheres (NESs) derived from CHA-hES3 were cultured with or without DAPT (5 M) for 4 days. Rosette-like folded struc-
tures in NESs were markedly reduced with DAPT treatment. CHA3 hESCs were used. Scale bars, 500 m. (B) DAPT-induced 
loss of rosette structures. DAPT treatment removes rosettes from attached NES clumps whereas the DMSO control group 
still contains rosettes. H9 hESCs were used. Scale bars, 200 m. (C) Reduction in volume of the DAPT-treated NESs. The vol-
ume of NESs after DAPT treatment for 4 days was measured. Control group (black) was estimated as 0.066 ± 0.042 mm3 
(mean ± standard deviation (SD); n = 44) and the DAPT group (red) was 0.039 ± 0.027 mm3 (n = 58). The difference between 
the two groups was significant (p < 0.001). In the box plot, box percentage and mean values (open squares) are indicated. 
Whiskers range from 595%. 'x' in each box indicates an upper and lower extreme value. (D) RT-PCR results. Neural stem cell 
marker genes (SOX1, VIM, and NES) and Notch-regulated target genes (HES1 and HES5) showed reduced expression levels in 
DAPT-treated NESs derived from CHA3 and H9 hESCs. However, expression of the pro-neuronal genes, NGN1 and MASH1, 
were reversely increased by DAPT-treatment. (E) Neuroectodermal sphere-reforming assay. NESs were dissociated into sin-
gle cells and cultured for 1718 days with (gray) or without (black) DAPT (5 M). Among the newly formed NESs, those larger 
than 50 m diameter were counted. The values denote mean ± standard error and there are significant differences between 
the control and the DAPT-treated groups (p < 0.05). Experiments were independently performed three times. (F) BrdU incor-
poration assay. The proportion of mitotically active cells was reduced in DAPT-treated NESs. The statistical values denote 
mean ± standard error, and 'n' indicates the number of cells counted. Data were obtained from more than three (CHA3, p < 
0.05) or five (H9, p < 0.005) independent experiments.BMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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Inhibition of Notch signaling directs cells of neuroectodermal spheres to differentiate into neuronal cells Figure 4
Inhibition of Notch signaling directs cells of neuroectodermal spheres to differentiate into neuronal cells. (A) 
Immunostaining of attached NESs for TUJ1. NESs derived from H9 hESCs were treated with DMSO or DAPT for 4 days and 
stained for TUJ1 (green). Images of NESs are shown in parts in a and b or as whole clumps in c and d. In d, two consecutive 
pictures separately taken are combined. (B-C) Measurement of TUJ1-positive cells after DAPT treatment. NESs cultured in 
the NSM containing DMSO (solid bars) or DAPT (gray bars) for 4 days were dissociated into single cells and attached on the 
matrigel-coated coverslip before immunostaining for TUJ1 (B) and Nestin (C). The number of positively stained cells relative 
to DAPI-positive cells was calculated. The values denote mean ± standard deviation and there are significant differences 
between the control and the DAPT-treated groups (p < 0.005 for TUJ1 and p < 0.001 for Nestin). Experiments were inde-
pendently performed five times and 2087 cells in total were counted. Results of Western-blot analyses of DMSO control and 
DAPT treated samples are shown in the boxes, in agreement with the results of cell counting. TUJ1 and MAP2 are neuronal 
markers, and S100, GFAP, NG2 and CNPase are glial markers. -Tubulin, a control for the bands in B and C. (D) Enrichment 
of neurite bundles by withdrawal of growth factors. The rosettes structures are clear, regardless of GF presence (arrowheads) 
but not visible in the DAPT-treated samples. Neurite formation was markedly accelerated in the DAPT-treated NESs after 
withdrawal of growth factors such as bFGF, LIF and EGF (arrows). Such neurite bundles are rarely seen in DAPT-treated NESs 
in the presence of growth factors. Scale bars, 200 m in A and 500 m in D.BMC Neuroscience 2009, 10:97 http://www.biomedcentral.com/1471-2202/10/97
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fore has a genuine role in the hESC-derived NESs, and we
obtained several results. First, results of RT-PCR and West-
ern-blot analyses showed that most of the known key
components of the Notch signaling pathway such as
receptors (NOTCH1, NOTCH2 and NOTCH3), ligands
(DLL1, DLL3 and JAG1), and regulators (NICD, MIB1,
MIB2 and PSEN1) were abundantly expressed in the NESs
at the protein and mRNA levels (Figure 2A and 2B). Sec-
ond, the expression levels of Notch signal members and
the resulting target genes (HES1 and HES5) were
increased in the NESs compared with those in the EBs.
This was particularly true for the NICD, DLL1, JAG1 and
HES1 (Figure 2B). Third, immunostaining of the NESs for
the plasma-membrane-bound ligand JAG1 and DLL1
demonstrated that both are localized mainly to the cells
comprising inner rims of the rosettes, rather than being
expressed throughout the NESs (Figure 2C). Fourth, the
treatment with Notch inhibitor DAPT removed rosette
structures from both floating and attached NESs, and was
associated with the reduction of NSC marker expressions
and proliferation potential in the NESs (Figure 3). Finally,
DAPT treatment induced neurite formation and increased
expression of TUJ1 (Figure 4), indicating that Notch inhi-
bition drives the NESs to differentiate preferentially into
neuronal cells, in agreement with the observation that
Notch-inhibited neuroprogenitor cells favor differentia-
tion toward neuronal cells in vertebrate and invertebrate
(for review, see [3]). Therefore, we concluded that Notch
signaling actively functions in the NESs or, more specifi-
cally, in the rosettes, and that Notch signaling is responsi-
ble for maintenance of the stem-cell features of NSCs or
neuroprogenitors in the rosettes. Therefore, our results
indicate that the hESC-derived NESs or the neural rosettes
are a good in-vitro model for neurogenesis in vivo.
Conclusion
NSCs have considerable therapeutic values in cell-replac-
ing-regenerative treatment of currently incurable neural
diseases. hESCs are one of the best sources of NSCs or
neuroprogenitor cells owing to their unlimited prolifera-
tion. In this study, we derived NESs containing neuropro-
genitors from hESCs, and verified that these hESC-derived
NESs were typical of neurospheres burying neuroprogeni-
tors and were characteristic of activated Notch signaling.
DAPT-induced inhibition of Notch signaling led to loss of
the stem-cell characteristics from the NESs and drove
them to differentiate into neuronal cells. These results are
the first to demonstrate the roles of Notch signaling in
hESC-derived NESs with biochemical features similar to
those in neurospheres derived from animal brains, or fetal
or adult human brains. Therefore, the hESC-derived NESs
or neural rosettes are considered to be a good in vitro
model for studying the neurogenesis that occurs in vivo.
We believe that our results might aid further study of the
mechanisms by which rosettes form and expand in vitro,
how neuroprogenitor cells maintain their stem-cell-like
characteristics in the cell culture environment, and the
stem-cell characteristics that lead to asymmetric division.
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